지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2023.3
- 수록면
- 220 - 231 (12page)
- DOI
- 10.4093/dmj.2021.0327
이용수
초록· 키워드
오류제보하기
Background: We investigated whether metabolic dysfunction-associated fatty liver disease (MAFLD) is associated with an elevated risk of all-cause and cardiovascular mortality using a large-scale health examination cohort.Methods: A total of 394,835 subjects in the Kangbuk Samsung Health Study cohort were enrolled from 2002 to 2012. Participants were categorized by the presence of nonalcoholic fatty liver disease (NAFLD) and MAFLD as follows: normal subjects; patients with both NAFLD and MAFLD; patients with NAFLD only; and patients with MAFLD only. Cox proportional hazards models were used to analyze the risk of mortality.Results: During a median 5.7 years of follow-up, 20.69% was patients with both NAFLD and MAFLD, 1.51% was patients with NAFLD only, and 4.29% was patients with MAFLD only. All-cause and cardiovascular death was higher in patients with MAFLD than those without MAFLD (P<0.001, respectively). In patients with MAFLD only, the hazard ratio (HR) of all-cause and cardiovascular death was 1.35 (95% confidence interval [CI], 1.13 to 1.60) and 1.90 (95% CI, 1.26 to 2.88) after adjusting for age, which lost its statistical significance by multivariable adjustments. Compared to patients with less than two components of metabolic dysfunction, patients with more than two components of metabolic dysfunction were a higher risk of cardiovascular death (HR, 2.05; 95% CI, 1.25 to 3.38) and only women with more than two components of metabolic dysfunction were a higher risk of all-cause death (HR, 1.44; 95% CI, 1.02 to 2.03).Conclusion: MAFLD criteria could identify a high-risk group for all-cause and cardiovascular death.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
MAFLD: How is it different from NAFLD?
Clinical and Molecular Hepatology
2023 .02
-
From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Clinical and Molecular Hepatology
2021 .01
-
Taiwan Association for the Study of the Liver-Taiwan Society of Cardiology Taiwan position statement for the management of metabolic dysfunction- associated fatty liver disease and cardiovascular diseases
Clinical and Molecular Hepatology
2024 .01
-
Healthy Lifestyle and the Risk of Metabolic Dysfunction-Associated Fatty Liver Disease: A Large Prospective Cohort Study
Diabetes and Metabolism Journal
2024 .09
-
Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease
Gut and Liver
2022 .09
-
Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease
Gut and Liver
2021 .01
-
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Clinical and Molecular Hepatology
2022 .04
-
Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis
Clinical and Molecular Hepatology
2024 .07
-
대사이상 관련 지방간질환의 생간건비탕 치험 1례
대한한방내과학회지
2023 .05
-
Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives
Clinical and Molecular Hepatology
2023 .04
-
Prevalence and risk factors of metabolic dysfunction-associated fatty liver disease in Korean air force army inclusive of pilots: 2020-2022
항공우주의학 학술대회
2024 .05
-
Fatty Liver Disease and Cardiovascular Risk: Impact of Metabolic Dysfunctions
Gut and Liver
2022 .07
-
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
Diabetes and Metabolism Journal
2023 .03
-
Nonalcoholic fatty liver disease and non-liver comorbidities
Clinical and Molecular Hepatology
2023 .02
-
Risk factors in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2023 .02
-
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Diabetes and Metabolism Journal
2019 .01
-
Non-alcoholic fatty liver disease-related hepatocellular carcinoma
Journal of Liver Cancer
2023 .03
-
Evaluation and Management of Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
Clinical and Molecular Hepatology
2021 .01
-
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Clinical and Molecular Hepatology
2022 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0